Concapk. Thx for the informed discussion re patents Some questions I thought Amarins key patent was the one issued late 2012 . This patent was for a composition DEVOID of DHA and method of action by which to lower TG’s
There was no “ prior art “ and not obvious that a composition devoid of DHA would lower Tgs ... which is why ( my understanding ) Amarin could get a patent since Epadel containing about 2% DHA existed and was obviously “ prior art “ .
Therefore any composition containing DHA was prior art and obvious .
That’s where Amarins patent claims run into trouble from my admittedly limited understanding . From the few of their patents that I’ve read they are claiming patents for compositions containing up to 20 % DHA
How could they claim for anything more then a composition DEVOID of DHA ... as there’s obviously prior art in DHA / EPA compositions .
Lovaza patent covered DHA / EPA composition and method of action to lower TGs ... but was invalidated since they allowed a test sample to be in the Public Domain before filing for their patent .
By the way Teva were paid $2m to go away BEFORE R-It results with the catch they could launch a generic if any other generic co won
I don’t see how anyone gets around the composition Devoid of DHA patent Do you ? Kiwi
Con. Correction. Key patents late 2011. Composition of matter devoid of DHA Method of action patent ... using a composition devoid of DHA to lower Tg’s How does a generic invalidate these It was not obvious and no prior art that a composition devoid of DHA would lower tgs .... thus Amarin was granted these patents Kiwi
Thank you for this well-informed detailed post. I too can't imagine AMRN's legal team didn't see this coming. Seems their patent attorney and the USPTO would have known that information was not included.
News 
Market Data 
Discover 
